BNTX BioNTech SE - ADR

$BNTX i got a feeling that this will goes to 92$+ before it'll want to go parabolic, to accumulate and generate shorts, short is literally 1% float at the moments.

$BNTX this data set is far above everything available today, its a MASSIVE SHIFT for SCLC for newbies, available therapies are: Topotecan: ORR 10–20 % Lurbinectedin: ORR 35 % DLL3‑ADCs: ORR 40–50 %, kinda toxic IO‑Rechallenge: ORR 5–15 % BNTX delivered with PUMI + ELFE: 👉 70 % ORR 👉 92 % ORR in First‑Line 👉 77 % ORR in Second‑Line 👉 52 % ORR in Third‑Line+ 👉 70 % ORR after DLL3‑Therapie !!! This will trigger a massive reevaluation of $BNTX !!! Their pipeline works, and they are unbeatable!

$BNTX Perhaps the biggest stock failure in the last 12 months. mRNA technology was so promising and BioNtech just squandered it all. Thankfully, I jettisoned this company early 2026 and went all in on Moderna. Any reason for a second look? Seems like dead money until new leadership takes the helm next year. Any catalysts between now and March of next year? They promised many positive surprises in 2026. 2026 was to be a great year . . .anyone?

$BNTX the pipeline is valued by the market at about 10B here. They have about 16B cash. Either there is something awry about their pipeline or the market is missing something. At the pandemic peak this was valued at 100B without much cash. Interest rates to blame I guess.

$BNTX MRNA's success against melanoma is like a child's play when compared to BNTX's success against small call lung cancer. The mRNA method has been used successfully against skin cancer for some time. The medical field knows about it. But SCLC is very tough. BNTX's P 1/2b data are not just great. It is wildly beyond what has been expected for SCLC. It is groundbreaking. Anyone who wants to downplay is either intentionally lying or extremely ignorant. JMO

$BNTX You fools think the science will make this move like Moderna but clearly the market doesn’t give a shit about the science. Moderna moved because it experienced a short squeeze, this doesn’t have the same setup. Furthermore it’s an ADR, and US equities experience the most volatility. It also doesn’t help that the founders dipped and that executive team members also sold shares recently. This is a multi-year play if they execute correctly, so don’t expect the same type of rise here.

$BNTX The market hates heavy insider owned stocks like BNTX (more than 50% owned by the insiders). The insiders should sell a minimum 80% of their holdings to JP Morgan, GS, and Morgan Stanley. Then the market will pump it for no apparent reasons.

$BNTX LOL The “market” will keep this between 97.50 and 100 this week, I bet. It will move up when the “market” movers are ready to profit from, eventually. Sooner than later, I hope. Fair value (for now) is 180+. JMO

$BNTX is not Moderna, Moderna is great because its US. They can flip a penny and the investors give it 50% plus. Meanwhile BNTX is very close to deliver a keytruda sucessor with 30 billion annual rev, but hey who cares! Fucking US fanboys should wake up!

$BNTX Still have their last presentation coming in in about 6-7 hours Phase 3 trial results Pop pop pop

$BNTX 'Survival Benefit: Median overall survival reached 18.5 months with gotistobart, compared to just 10.0 months for standard-of-care chemotherapy.' That is quite sad, that we're talking about months here. Still an improvement.

$BNTX PD-L1 x VEGF-A bispecific antibody plus B7H3 antibody-drug conjugate show 70.4% ORR

$BNTX Investors on here are so ridiculous. They are upset that Moderna moved but this didn’t. What does this tell us? It tells us that it’s not the science that moved Moderna, because if it was it should have never hit the $20’s. It was a short squeeze possibly caused by retailers accumulating on news and some short covering. So in time that will come down from the sky and meet this company in valuation. Based off the price action of BioNtech it is appropriately priced because its sales are years away from producing fruit, and even then its execution risk. So with that all being said, expect a gradual grinding of BNTX at current levels for the foreseeable future and Moderna to come back below $100 again because science alone isn’t enough, it’s cash flows that matter more and both are in negative territory.

$BNTX Also at WCLC… In unresectable malignant mesothelioma, in first-line pumitamig (BNT327/BMS-986545) plus chemotherapy, the updated Phase 2 analysis reported: * confirmed ORR: 51.6% * disease-control rate: 93.5% * median PFS: 16.6 months * median OS: 25.8 months

$BNTX obviously happy for my small holdings here, but really hopeful for the patients and the field. These guys are proving to be the best in class.

$BNTX nice safety profil too → 0 DLTs → Grade ≥3 TRAEs only 23.3 % → no ILD‑signals → no VEGF‑catastrophs → no ADC‑typic showstopper this is far better than most of available ADCs.

$BNTX Fake companies like moderna up 250 % + the past few months & novavax up But bntx stuck on stupid

$BNTX was not a comfortable play so far but bottom held. at some point they need to go, maybe now. and when they go, they need to go above (3) imho

$BNTX tired of posting..but you know the market is inefficient/irrational when compared with its other mRNA peer

$BNTX disappointing price action today, but happy for the patients. Hope the company helps improve the standard of care and realizes a good value in the long run.